Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02874924 · ClinicalTrials.gov registry record · Phase 2
Effect of mTOR Inhibition and Other Metabolism Modulating Interventions on the Elderly
A Phase 2 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT02874924 is a Phase 2 study that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 34 participants.
The verdict
NCT02874924, a Phase 2 study, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
The ability to mount an effective immune response declines with age, leaving the elderly increasingly susceptible to infectious diseases and cancer. Rapamycin, an FDA approved drug to prevent transplant rejection, increases the lifespan and healthspan of mice and ameliorates age-related declines in immune responsiveness, cancer survival, and cognition in laboratory animals. Investigators are conducting a translational trial to test whether rapamycin also improves life functions in humans focusing on elderly persons (aged 70-95).
Interventions
- DRUG Placebo
- DRUG Rapamycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2016-06 |
| Est. Completion | 2018-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02874924
The ClinicalTrials.gov registry entry for NCT02874924 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02874924 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02874924 about?
NCT02874924 is a clinical study titled "Effect of mTOR Inhibition and Other Metabolism Modulating Interventions on the Elderly". The ability to mount an effective immune response declines with age, leaving the elderly increasingly susceptible to infectious diseases and cancer. Rapamycin, an FDA approved drug to prevent transplant rejection, increases the lifespan and healthspan of mice and ameliorates age-related declines in ...
What is the current status of trial NCT02874924?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2016-06. Estimated completion is 2018-09.
What interventions are being tested in trial NCT02874924?
The interventions under investigation include: Placebo (DRUG), Rapamycin (DRUG).
Who is sponsoring clinical trial NCT02874924?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.